Rexgenero readies cell therapy for Critical Limb Ischemia Phase III

Founded as recently as 2014, Rexgenero is poised to start two Phase III trials of its lead candidate Rexmyelocel-T (REX-001) in patients with Critical Limb Ischemia. CEO Dr. Joe Dupere tells Mike Ward, Informa Pharma Intelligence’s insights global director of content, that the London-based cell therapy company is seeking new investors and potential partners for Asian and Middle Eastern markets.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Joe Dupere – CEO, Rexgenero Ltd